MedTrace Logo

The Immunogenicity and Safety of V-01-351/V-01D Bivalence Vaccine

NCT05273528 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-03-10

No results posted yet for this study

Summary

It is a Single Arm, Open Label Clinical Study to Evaluate the Immunogenicity and Safety of Sequential Immunization of V-01-351/V-01D Bivalence Vaccine in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of Inactivated Vaccines. A total of 20 participants were enrolled.

Conditions

  • COVID-19 Pandemic

Interventions

BIOLOGICAL

Recombinant SARS-CoV-2 Beta Variant Fusion Protein Vaccine/Recombinant SARS-CoV-2 Delta Variant Fusion Protein Vaccine

The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.

Sponsors & Collaborators

  • Livzon Pharmaceutical Group Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-11
Primary Completion
2023-01-06
Completion
2023-01-06

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05273528 on ClinicalTrials.gov